242 related articles for article (PubMed ID: 19886242)
1. [Safety of PLD in the treatment of the patients with recurrent ovarian cancer--clinical experience].
Malkowska-Walczak B; Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2009 Sep; 80(9):682-6. PubMed ID: 19886242
[TBL] [Abstract][Full Text] [Related]
2. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
3. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF
Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420
[TBL] [Abstract][Full Text] [Related]
6. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
[TBL] [Abstract][Full Text] [Related]
7. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
8. [Pegylated liposomal doxorubicin in ovarian cancer treatment].
Nowak-Markwitz E
Ginekol Pol; 2009 Aug; 80(8):615-9. PubMed ID: 19824461
[TBL] [Abstract][Full Text] [Related]
9. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
[TBL] [Abstract][Full Text] [Related]
10. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
11. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421
[TBL] [Abstract][Full Text] [Related]
13. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
14. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Tas F; Guney N; Derin D; Aydiner A; Topuz E
Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Carta G; Necozione S; Mantovani G; Rea S
Gynecol Oncol; 2007 Jul; 106(1):164-9. PubMed ID: 17481704
[TBL] [Abstract][Full Text] [Related]
16. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
[TBL] [Abstract][Full Text] [Related]
17. Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
Herzog TJ; Kutarska E; Bidzińsk M; Symanowski J; Nguyen B; Rangwala RA; Naumann RW
Int J Gynecol Cancer; 2016 Nov; 26(9):1580-1585. PubMed ID: 27654255
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
Shoji T; Takatori E; Omi H; Kagabu M; Honda T; Futagami M; Yokoyama Y; Kaiho M; Tokunaga H; Otsuki T; Takano T; Yaegashi N; Kojimahara T; Ohta T; Nagase S; Soeda S; Watanebe T; Nishiyama H; Sugiyama T
Cancer Chemother Pharmacol; 2017 Aug; 80(2):355-361. PubMed ID: 28656383
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
Vergote I; Finkler NJ; Hall JB; Melnyk O; Edwards RP; Jones M; Keck JG; Meng L; Brown GL; Rankin EM; Burke JJ; Boccia RV; Runowicz CD; Rose PG
Int J Gynecol Cancer; 2010 Jul; 20(5):772-80. PubMed ID: 20973267
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
Chambers LM; Pendlebury A; Rose PG; Yao M; DeBernardo R
Gynecol Oncol; 2020 Aug; 158(2):309-315. PubMed ID: 32499072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]